ADVERTISEMENT

2017 Update on obstetrics

These experts discuss the practical clinical implications of new society recommendations for antenatal steroid administration, low-dose aspirin for preeclampsia prevention, chromosomal microarray analysis, and Zika virus infection and pregnancy
OBG Management. 2017 January;29(1):36-40, 42
January 4, 2017|OBG Management
Jaimey M. Pauli, MD;John T. Repke, MD
Author and Disclosure Information


Dr. Pauli is Associate Professor, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Penn State University College of Medicine, and Attending Perinatologist at the Milton S. Hersey Medical Center in Hershey, Pennsylvania.

 


Dr. Repke is University Professor and Chairman, Department of Obstetrics and Gynecology, Penn State University College of Medicine, and Obstetrician-Gynecologist-In-Chief, The Milton S. Hershey Medical Center, Hershey, Pennsylvania. Dr. Repke serves on the OBG Management Board of Editors.

 

The authors report no financial relationships relevant to this article.

In this article

In this Update we discuss several exciting new recommendations for preventive treatments in pregnancy and prenatal diagnostic tests. Our A-to-Z coverage includes:

  • antenatal steroids in late preterm pregnancy
  • expanded list of high-risk conditions warranting low-dose aspirin for preeclampsia prevention
  • chromosomal microarray analysis versus karyotype for specific clinical situations
  • Zika virus infection evolving information.

Next: New recommendation for timing of late preterm antenatal steroids

,false
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT